Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q1 2024 · 10-Q
Revenue$72.97M$72.97M+73.6% vs Q1 2023 Net Income-$2.53M-$2.53MN/M vs Q1 2023 EPS Diluted-$0.09-$0.09N/M vs Q1 2023 Operating Income-$5,471,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,987,000N/M Margins · derivedOperating margin-7.5%+67.5 pt vs Q1 2023
Net margin-3.5%+66.0 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end